(Q35994823)

11 August 2017

1 reference

title

Homoharringtonine: a new treatment option for myeloid leukemia (English)

1 reference

11 August 2017

Chang Ying Luo

1

1 reference

11 August 2017

Jing Yan Tang

series ordinal

2

1 reference

11 August 2017

Yao Ping Wang

series ordinal

3

1 reference

11 August 2017

publication date

1 August 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

9

1 reference

11 August 2017

issue

4

1 reference

11 August 2017

page(s)

259-270

1 reference

Inhibition of Protein Synthesis in Intact HeLa Cells

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Selective inhibition of the polypeptide chain elongation in eukaryotic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Ribosomal resistance to the 12,13-epoxytrichothecene antibiotics in the producing organism Myrothecium verrucaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Binding of [3H]narciclasine to eukaryotic ribosomes A study on a structure-activity relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Cytotoxicity and cell cycle specificity of homoharringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Modulation of drug resistance in homoharringtonine-resistant C-1300 neuroblastoma cells with cyclosporine A and dipyridamole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Reversal of C1300 murine neuroblastoma multidrug resistance by cremophorEL, a solvent for cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

A homoharringtonine-based regimen for childhood acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330410001714194

10.1080/10245330410001714194

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference